clinafloxacin has been researched along with Bacterial Disease in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bridges, AJ; Culbertson, TP; Domagala, JM; Gambino, L; Hagen, SE; Karrick, G; Porter, K; Sanchez, JP; Sesnie, JA; Spense, FG | 1 |
| Damu, GL; Geng, RX; Lv, JS; Wang, Y; Yang, DC; Zhou, CH | 1 |
| Ba, Y; Hou, X; Wang, S; Xu, Z; Yang, H; Zhang, J | 1 |
| Finegold, SM; Molitoris, E; Reeves, D; Wexler, HM | 1 |
| Eiseman, IA; McGuire, NM; Tack, KJ | 1 |
| Goldstein, EJ | 1 |
| Cohen, MA; Gage, JW; Huband, MD; Roland, GE; Yoder, SL | 1 |
| Deshpande, LM; Diekema, DJ; Jones, RN | 1 |
| Bennion, RS; Christou, NV; Dellinger, EP; Pak, R; Rotstein, OD; Solomkin, JS; Tack, K; Wilson, SE | 1 |
| Christou, N; Eiseman, I; Siami, G; Tack, KJ | 1 |
| Brennscheidt, U; Cornely, O; Figuera, A; Glauser, MP; Grigg, A; Keyserling, C; Tack, K; Trostmann, U; Welling, L | 1 |
| Shah, P; Tack, K; Trostmann, U | 1 |
| Allen, SD; Barry, AL; Fuchs, PC; Gerlach, EH; Pfaller, MA | 1 |
2 review(s) available for clinafloxacin and Bacterial Disease
| Article | Year |
|---|---|
Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
Topics: Anti-Bacterial Agents; Bacterial Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Nitroimidazoles | 2019 |
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Safety; Syndrome | 1996 |
5 trial(s) available for clinafloxacin and Bacterial Disease
| Article | Year |
|---|---|
Initial clinical experience with clinafloxacin in the treatment of serious infections.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Child; Ciprofloxacin; Drug Resistance, Multiple; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Middle Aged; Quinolones | 1995 |
Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.
Topics: Abdomen; Adult; Anti-Infective Agents; Bacterial Infections; Cilastatin; Double-Blind Method; Female; Fluoroquinolones; Humans; Imipenem; Logistic Models; Male; Middle Aged; Prospective Studies; Protease Inhibitors; Thienamycins | 2001 |
Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; beta-Lactamase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fluoroquinolones; Humans; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Skin Diseases, Infectious; Tazobactam | 2001 |
Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fever; Fluoroquinolones; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Teicoplanin; Treatment Outcome; Vancomycin | 2002 |
Open-label, multicentre, emergency-use study of clinafloxacin (CI-960) in the treatment of patients with serious life-threatening infections.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Critical Illness; Cross Infection; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gastrointestinal Diseases; Humans; Male; Middle Aged; Respiratory Tract Infections; Treatment Failure | 2002 |
6 other study(ies) available for clinafloxacin and Bacterial Disease
| Article | Year |
|---|---|
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
Topics: Alkylation; Aminoquinolines; Animals; Anti-Bacterial Agents; Bacterial Infections; Chemical Phenomena; Chemistry; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Hydroxyquinolines; Mice; Microbial Sensitivity Tests; Molecular Structure; Piperazines; Pyrrolidines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1991 |
Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Drug Design; Fluoroquinolones; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mycoses; Staphylococcal Infections; Triazoles | 2012 |
In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Culture Media; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1994 |
Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Mice; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1998 |
Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitals; Humans; Microbial Sensitivity Tests; United States | 1999 |
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines | 1991 |